Jack Anders Sells 20,000 Shares of Revolution Medicines (NASDAQ:RVMD) Stock

Posted by Brian Himes on Jun 26th, 2026

Revolution Medicines, Inc. (NASDAQ:RVMD – Get Free Report) CFO Jack Anders sold 20,000 shares of Revolution Medicines stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $168.33, for a total transaction of $3,366,600.00. Following the transaction, the chief financial officer directly owned 123,269 shares in the company, valued at approximately $20,749,870.77. This represents a 13.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Jack Anders also recently made the following trade(s):

On Tuesday, June 16th, Jack Anders sold 2,722 shares of Revolution Medicines stock. The shares were sold at an average price of $156.12, for a total transaction of $424,958.64.

Revolution Medicines Trading Up 2.2%

Shares of RVMD traded up $3.91 during trading hours on Friday, reaching $182.08. The stock had a trading volume of 9,539,559 shares, compared to its average volume of 3,377,479. The company has a market cap of $38.71 billion, a P/E ratio of -25.75 and a beta of 1.40. Revolution Medicines, Inc. has a 52 week low of $34.00 and a 52 week high of $184.39. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.19. The firm has a 50-day moving average of $151.19 and a 200 day moving average of $116.22.

Revolution Medicines (NASDAQ:RVMD – Get Free Report) last posted its earnings results on Wednesday, May 6th. The company reported ($2.29) earnings per share for the quarter, missing the consensus estimate of ($1.83) by ($0.46). During the same period in the previous year, the company posted ($1.13) earnings per share. On average, sell-side analysts expect that Revolution Medicines, Inc. will post -7.94 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Revolution Medicines in a research report on Tuesday, April 21st. Oppenheimer lifted their price target on shares of Revolution Medicines from $165.00 to $195.00 and gave the company an “outperform” rating in a research note on Monday, June 1st. Piper Sandler upped their price target on shares of Revolution Medicines to $172.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. HC Wainwright increased their price objective on shares of Revolution Medicines from $169.00 to $195.00 and gave the stock a “buy” rating in a research report on Monday, June 1st. Finally, Jefferies Financial Group initiated coverage on shares of Revolution Medicines in a report on Monday, March 16th. They set a “buy” rating on the stock. Three analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Revolution Medicines has an average rating of “Buy” and a consensus price target of $123.72.

Get Our Latest Stock Analysis on RVMD

Institutional Investors Weigh In On Revolution Medicines

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in Revolution Medicines by 6.7% in the 4th quarter. Vanguard Group Inc. now owns 16,719,886 shares of the company’s stock valued at $1,331,739,000 after acquiring an additional 1,056,792 shares in the last quarter. Farallon Capital Management LLC grew its stake in shares of Revolution Medicines by 2.1% during the 3rd quarter. Farallon Capital Management LLC now owns 14,625,692 shares of the company’s stock worth $683,020,000 after acquiring an additional 300,000 shares in the last quarter. Janus Henderson Group PLC grew its stake in shares of Revolution Medicines by 8.3% during the 4th quarter. Janus Henderson Group PLC now owns 12,303,502 shares of the company’s stock worth $980,036,000 after acquiring an additional 947,448 shares in the last quarter. Baker BROS. Advisors LP raised its holdings in shares of Revolution Medicines by 1.0% in the third quarter. Baker BROS. Advisors LP now owns 9,455,357 shares of the company’s stock valued at $441,565,000 after purchasing an additional 90,385 shares during the last quarter. Finally, Nextech Invest Ltd. raised its holdings in shares of Revolution Medicines by 20.7% in the fourth quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock valued at $332,472,000 after purchasing an additional 1,304,347 shares during the last quarter. Institutional investors and hedge funds own 94.34% of the company’s stock.

About Revolution Medicines

(Get Free Report)

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.